PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical…
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…
LOS ANGELES--(BUSINESS WIRE)--WhiteHawk Capital Partners: WhiteHawk Capital Partners has provided a $70 million senior secured term loan to an online…
STOCKHOLM, June 13, 2025 /PRNewswire/ -- The Curt Bergfors Foundation is honored to announce that NitroCapt was awarded the Food Planet…
VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal…
To drive innovation, Alghanim Industries is unveiling Sama X, a bold new tech venture and authorized Starlink global reseller that brings…
SAN FRANCISCO--(BUSINESS WIRE)--ZeroError, today announced at Snowflake’s annual user conference, Snowflake Summit 2025, the launch of new advanced analytics capabilities…
TROPION-Lung02 and TROPION-Lung04 phase 1b results support combination of Daiichi Sankyo and AstraZeneca’s DATROWAY with immunotherapy as first-line treatment for…
TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement…
Two pioneering scientists received The Brain Prize 2025 for their discoveries that open an entirely new way of thinking about…